Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
KROS Quote, Financials, Valuation and Earnings
Last price:
$12.02
Seasonality move
:
-17.98%
Day range:
$11.30 - $12.03
52-week range:
$9.12 - $22.55
Dividend yield:
0%
P/E ratio:
6.77x
P/S ratio:
1.89x
P/B ratio:
0.80x
Volume:
559K
Avg. volume:
533.9K
1-year change:
19.52%
Market cap:
$243.2M
Revenue:
$244.1M
EPS (TTM):
$1.82
Analysts' Opinion
-
Consensus RatingKeros Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.57, Keros Therapeutics, Inc. has an estimated upside of 88.1% from its current price of $12.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing -- downside risk from its current price of $12.00.
Fair Value
-
According to the consensus of 9 analysts, Keros Therapeutics, Inc. has 88.1% upside to fair value with a price target of $22.57 per share.
KROS vs. S&P 500
-
Over the past 5 trading days, Keros Therapeutics, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Keros Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Keros Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Keros Therapeutics, Inc. reported revenues of $385K.
Earnings Growth
-
Keros Therapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Keros Therapeutics, Inc. reported earnings per share of -$0.86.
Enterprise value:
-33.9M
EV / Invested capital:
--
Price / LTM sales:
1.89x
EV / EBIT:
-0.50x
EV / Revenue:
-0.14x
PEG ratio (5yr expected):
-0.40x
EV / Free cash flow:
-0.32x
Price / Operating cash flow:
4.35x
Enterprise value / EBITDA:
-0.49x
Gross Profit (TTM):
$242.6M
Return On Assets:
13.42%
Net Income Margin (TTM):
35.65%
Return On Equity:
14.44%
Return On Invested Capital:
14.02%
Operating Margin:
-7581.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $151K | $3.6M | $244.1M | $3M | $385K | |
| Gross Profit | -$1.9M | $2.3M | $242.6M | $2.7M | -$15K | |
| Operating Income | -$169.9M | -$210.8M | $67.7M | -$53.3M | -$29.2M | |
| EBITDA | -$167.9M | -$209.6M | $69.2M | -$52.9M | -$28.8M | |
| Diluted EPS | -$5.19 | -$5.01 | $1.82 | -$1.14 | -$0.86 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $251.4M | $285.8M | $347.3M | $588.9M | $315.4M | |
| Total Assets | $255.3M | $306.8M | $370M | $615.9M | $342.9M | |
| Current Liabilities | $11.8M | $16.5M | $24.4M | $27.5M | $20.4M | |
| Total Liabilities | $12.1M | $29.4M | $37.8M | $44.3M | $39.7M | |
| Total Equity | $243.2M | $277.4M | $332.2M | $571.6M | $303.1M | |
| Total Debt | $231K | $12.8M | $13.4M | $16.9M | $14.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$124.5M | -$160.9M | $107.5M | -$46M | -$27.3M | |
| Cash From Investing | -$2.5M | -$1.9M | -$1.6M | -$289K | -$134K | |
| Cash From Financing | $179M | $391.8M | -$378.5M | $75.5M | -$378.6M | |
| Free Cash Flow | -$127M | -$162.8M | $106M | -$46.3M | -$27.4M | |
KROS
Sector
Market Cap
$243.2M
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
95.24%
-1.9%
1-Year Price Total Return
19.52%
-18.29%
Beta (5-Year)
0.984
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.18
200-day SMA
Sell
Level
$15.78
Bollinger Bands (100)
Sell
Level
13.36 - 20.14
Chaikin Money Flow
Buy
Level
15.8M
20-day SMA
Buy
Level
$11.18
Relative Strength Index (RSI14)
Sell
Level
46.99
ADX Line
Sell
Level
50.92
Williams %R
Sell
Level
-1.8576
50-day SMA
Sell
Level
$14.43
MACD (12, 26)
Sell
Level
-0.82
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
8.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.4649)
Buy
CA Score
(Annual)
Level (2.2916)
Sell
Beneish M-Score
(Annual)
Level (57.902)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-8.8273)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Stock Forecast FAQ
In the current month, KROS has received 5 Buy ratings 4 Hold ratings, and 0 Sell ratings. The KROS average analyst price target in the past 3 months is $22.57.
-
Where Will Keros Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Keros Therapeutics, Inc. share price will rise to $22.57 per share over the next 12 months.
-
What Do Analysts Say About Keros Therapeutics, Inc.?
Analysts are divided on their view about Keros Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Keros Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Keros Therapeutics, Inc.'s Price Target?
The price target for Keros Therapeutics, Inc. over the next 1-year time period is forecast to be $22.57 according to 9 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is KROS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Keros Therapeutics, Inc. is a Buy. 5 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KROS?
You can purchase shares of Keros Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Keros Therapeutics, Inc. shares.
-
What Is The Keros Therapeutics, Inc. Share Price Today?
Keros Therapeutics, Inc. was last trading at $12.02 per share. This represents the most recent stock quote for Keros Therapeutics, Inc.. Yesterday, Keros Therapeutics, Inc. closed at $12.00 per share.
-
How To Buy Keros Therapeutics, Inc. Stock Online?
In order to purchase Keros Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KROS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KROS
Sector
P/E ratio
6.77x
21.37x
PEG ratio
-0.40x
-0.01x
P/B ratio
0.80x
1.72x
Price / LTM sales
1.89x
1.44x
Growth Metrics
KROS
Sector
Revenue growth
-87.34%
3.44%
Earnings growth
24.4%
14.97%
Revenue (5-year growth)
-18.71%
6.27%
Earnings forecast
-$1.16
-$0.22
Profitability
KROS
Sector
Profitability FY 2025
$242.6M
$2.4M
Return on invested capital
14.02%
-33.43%
Return on assets
13.42%
-29.45%
Return on equity
14.44%
-40.29%
Earnings Date
Last Earnings Date
Mar
4
Next Earnings Date
May
11
Estimated Next Earnings Date
Jun
3
Balance Sheet
KROS
Sector
Total cash
$287.4M
$25.6M
Short term investments
--
$22.7M
Total assets
$342.9M
$70.4M
Long term debt
$14.5M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
